Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Cantor

In a Crowded ETF Market, This One Might Be the Riskiest

MicroStrategy is a good stock to own if you are bullish about Bitcoin's long-term prospects. For investors with a higher risk profile, the MSTX ETF might also seem attractive.

3 Cathie Wood Biotech Stocks That Analysts Expect to Double

3 Cathie Wood Biotech Stocks That Analysts Expect to Double

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Acreage Holdings: Analyst Increases Price Target To $1.44 And Remains Neutral

Acreage Holdings, Inc. (OTCQX: ACRDF) reported its financial results on Monday for the third quarter that ended September 30, 2022 (“Q3 2022”).

Jushi Holdings Will Soon Announce 3Q, Analyst Puts Price Target At $2.25 And Maintains Neutral Rating

Jushi Holdings Inc. (CSE: JUSH) (OTCQX: JUSHF) will announce its financial results for the third quarter before the market opens on Monday, November 14, 2022.

Where Is The Cheapest Weed In America? A Close Look At Cannabis Pricing In PA And FL

Pablo Zuanic from Cantor Fitzgerald offered an industry update, covering cannabis pricing in Pennsylvania and Florida based on retailers’ menus. “Think of this report as 'food for thought' - we are not adjusting estimates or our investment views,” Zuanic said.

Anshu Jain, Deutsche Bank chief in a pivotal era, dies at 59

Anshu Jain, Cantor Fitzgerald’s president who was known for his time leading Deutsche Bank traders into the lender’s investment banking heights, died five years after being diagnosed with duodenal cancer. He was 59.

Tribune News Service

inkl

Read news from The Economist, FT, and more,
with one subscription

Cantor Analayst Pablo Zuanic Believes SAFE Banking Now "The Worst Case Scenario" in 2022

Cantor Analayst Pablo Zuanic Believes SAFE Banking Now "The Worst Case Scenario" in 2022

In perhaps a sign that incremental progress on federal cannabis reform is afoot, some Wall Street analysts are increasingly coming around on the idea that reform can happen this year. Cantor Fitzgerald analyst Pablo Zuanic, a noted skeptic on SAFE Banking, now believes the legislation has a real chance of…

Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data

Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data

Celldex Therapeutics Inc's (NASDAQ:CLDX) shares closed almost 16% down on Friday after releasing Phase 1b study data of barzolvolimab. Cantor says the main reason for stock being down is the four patient adverse events on the generally transient, asymptomatic, and mild neutrophil decreases, noting a single Grade 3 case. One patient had values…

Read Why Cantor Upgraded Aurora Cannabis Stock

Read Why Cantor Upgraded Aurora Cannabis Stock

Cantor Fitzgerald has upgraded Aurora Cannabis Inc (NASDAQ: ACB) to Overweight from Neutral

This Mid-Cap Firm Can Potentially Offer Biggest Oral Drug In Atopic Dermatitis, Cantor Thinks So

This Mid-Cap Firm Can Potentially Offer Biggest Oral Drug In Atopic Dermatitis, Cantor Thinks So

Cantor assumes coverage of RAPT Therapeutics Inc (NASDAQ:RAPT) with an Overweight rating and a price target of $44 (vs. $58 previously). The analyst says the company's RPT193 (lead inflammation drug) could be a $3 billion drug in just atopic dermatitis (AD) indication, as it expects AD to outperform psoriasis. Cantor suggests that ‘193 is…

Peak Sales Potential For This ENT-Focused Stock Is Under-Appreciated, Says Cantor

Peak Sales Potential For This ENT-Focused Stock Is Under-Appreciated, Says Cantor

Cantor initiated coverage on Lyra Therapeutics Inc (NASDAQ:LYRA) with an Overweight rating and a price target of $15 (166% upside). According to the analyst, Lyra product pipeline's peak sales potential is under-appreciated, and it expects upward earnings estimate revisions to potentially move LYRA's stock higher. LYRA is well-positioned with a portfolio of products to…

Cannabis Analyst Advises Not To Buy WeedMaps Shares Until March

Cannabis Analyst Advises Not To Buy WeedMaps Shares Until March

Cantor Fitzgerald has issued a new report on cannabis tech platform WeedMaps (NASDAQ: MAPS), also known as WM Technology Inc.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Cantor Fitzgerald

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

325,839 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play